Medical Researcher and Philanthropist Laszlo Bito Dies at 87

His work contributed to the development of the drug Xalatan, a treatment for glaucoma.

Written byChloe Tenn
| 2 min read
man and woman sitting with bookshelves
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

On November 14, ocular physiologist and creative arts philanthropist Laszlo Bito passed away from chronic obstructive pulmonary disorder, a condition that stemmed from his time as a forced laborer in a Hungarian coal mine, according to The New York Times.

Bito was born in 1934 in Budapest, and in 1951, he and his family were deported from the city by the Hungarian communist regime, according to his website’s biographical timeline. He ended up in the city of Komlo where we was forced to work in the coal mines. He became a local leader in a revolt against such forced labor, but when the revolution failed, he escaped to Austria. He was granted asylum in the United States in 1956. There, Bito earned a degree in chemistry from Bard College in New York. He went on to earn his PhD in medical cell biology and biophysics from Columbia University in 1963, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • young woman smiling

    Chloe Tenn is a graduate of North Carolina State University, where she studied neurobiology, English, and forensic science. Fascinated by the intersection of science and society, she has written for organizations such as NC Sea Grant and the Smithsonian. Chloe also works as a freelancer with AZoNetwork, where she ghostwrites content for biotechnology, pharmaceutical, food, energy, and environmental companies. She recently completed her MSc Science Communication from the University of Manchester, where she researched how online communication impacts disease stigma. You can check out more of her work here.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies